New evidence and tools targeted risk estimation and monitoring across kidney and cardiovascular disease. A retrospective EHR analysis reported that people with insulin-treated diabetes and CKD or high risk for CKD who started real-time continuous glucose monitoring experienced slower kidney function decline and larger HbA1c improvements versus matched non-users. In parallel, a clinical decision support tool presented for ASN Kidney Week 2026 aimed to automate CKD identification, risk classification, and guideline-based treatment recommendations within primary care electronic health records. Together, the work points to a practical direction: using continuous monitoring to improve metabolic control while pairing it with workflow-integrated decision support to standardize early identification and treatment. For implementation, clinicians will look for how these systems affect outcomes over time and whether they reduce variation in care, particularly in primary-care settings.